智云健康(09955.HK) 宣布，全资子公司杭州康晟、江苏智云及91健康上海，于上日(30日)与不同买方订立股份转让协议，出售5间子公司股权，合共涉资7,951.64万元人民币。其中，杭州康晟拟向启联医疗管理出售所持有启联医药全部55%股权，代价为3,351.64万元人民币。
杭州康晟并与Zhu Qiuna订立股份转让协议，出售新万格医疗科技的30%股权，代价为3,200万元人民币，完成出售后杭州康晟仍持有新万格医疗科技25%股权。江苏智云同样与Zhu Qiuna订立股份转让协议，向其出售万迪生物的65%股权，代价为300万元人民币，完成出售后江苏智云将持有万迪生物科技的25%股权。
另外，91健康上海与上海略语订立股份转让协议，向其出售正和科学仪器的75%股权及江苏成升的35%股权，代价分别为800万元人民币及出售300万元人民币。完成交易后，91健康上海仍持有正和科学仪器及江苏成升各25%股权。(gc/da)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.